Spyre Therapeutics Inc. Cash Flow Conversion Efficiency
Spyre Therapeutics Inc. cash flow conversion efficiency. Based on the latest financial reports, Spyre Therapeutics Inc. (SYRE) has a cash flow conversion efficiency ratio of -0.063x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-69.88 Million) by net assets ($1.10 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Spyre Therapeutics Inc. (2014–2025)
Cash flow conversion efficiency of Spyre Therapeutics Inc. from 2014 to 2025. This chart illustrates how Spyre Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View SYRE live share price for real-time trading data and today's change.
Spyre Therapeutics Inc. Cash Flow Conversion Ratio Explained
Spyre Therapeutics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Spyre Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spyre Therapeutics Inc. ranked by their cash flow conversion efficiency. Also see how much is Spyre Therapeutics Inc. worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Everbright Securities Co Ltd
SHG:601788
|
0.110x |
|
Vanguard International Semiconductor
TWO:5347
|
0.092x |
|
XPENG INC. CL.A DL-00001
F:8XP
|
N/A |
|
National Retail Properties Inc
NYSE:NNN
|
0.029x |
|
Jackson Financial Inc
NYSE:JXN
|
0.106x |
|
CelcomDigi Berhad
KLSE:6947
|
0.030x |
|
Henry Schein Inc
NASDAQ:HSIC
|
-0.020x |
|
Sinoma Science & Technology Co Ltd
SHE:002080
|
0.061x |
Annual Cash Flow Conversion Efficiency for Spyre Therapeutics Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of Spyre Therapeutics Inc. from 2014 to 2025. Review SYRE free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $715.24 Million | $-169.25 Million | -0.237x | +22.16% |
| 2024-12-31 | $517.80 Million | $-157.41 Million | -0.304x | +44.01% |
| 2023-12-31 | $184.02 Million | $-99.91 Million | -0.543x | +65.92% |
| 2022-12-31 | $50.30 Million | $-80.14 Million | -1.593x | -148.96% |
| 2021-12-31 | $83.94 Million | $-53.72 Million | -0.640x | -18.09% |
| 2020-12-31 | $139.83 Million | $-75.78 Million | -0.542x | +50.44% |
| 2019-12-31 | $60.08 Million | $-65.69 Million | -1.093x | -129.01% |
| 2018-12-31 | $67.43 Million | $-32.19 Million | -0.477x | +2.36% |
| 2017-12-31 | $50.34 Million | $-24.61 Million | -0.489x | -63.43% |
| 2016-12-31 | $62.97 Million | $-18.84 Million | -0.299x | +1.63% |
| 2015-12-31 | $36.10 Million | $-10.98 Million | -0.304x | +92.24% |
| 2014-12-31 | $1.87 Million | $-7.33 Million | -3.918x | -- |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative … Read more